Piramal Pharma Limited Reports Strong Q2 and H1 FY27 Financial Results with Notable Growth Metrics
Overview
Piramal Pharma Limited, a globally renowned player in the pharmaceutical, health, and wellness industries, reported its financial results for the second quarter (Q2) and first half (H1) of the fiscal year 2027 (FY27), which ended on September 30, 2026. The results indicate a robust growth trajectory across all sectors of the company, showcasing sustained operational efficiency and profitability enhancements.
Key Financial Highlights
The consolidated financial results demonstrated robust performance metrics:
- - Revenue from ongoing operations reached ₹2,617 crores in Q2 FY27, marking a significant 28% year-over-year increase. Cumulatively, for H1 FY27, revenue stood at ₹4,887 crores, reflecting a 23% growth compared to the previous fiscal year.
- - The Contract Development and Manufacturing Organization (CDMO) segment contributed ₹1,424 crores for Q2, up 36% from the previous year, while the Consumer Healthcare (PCH) segment rose 14% driven by strong product performance.
- - EBITDA soared to ₹385 crores in Q2, representing a 72% surge year-over-year. This translated into an EBITDA margin of 14.7%, an increase of 350 basis points from the previous year.
Growth Drivers
Expanding Market Presence
Piramal Pharma's impressive revenue surge can be attributed to several key factors:
1. Strong Demand Across Business Segments: The company experienced broad-based revenue growth, driven by increased customer engagement and operational excellence across its three core business units—CDMO, Complex Hospital Generics (CHG), and Consumer Healthcare.
2. Enhanced Profitability: The improved EBITDA margin is a result of higher capacity utilization, operational leverage, and sustainable cost optimization initiatives.
3. New Client Acquisition: The first half of FY27 witnessed the acquisition of 22 new customers, along with successful completion of 110 customer audits, underscoring robust demand and customer trust in the company’s offerings.
Continuous Improvement in Quality Standards
Piramal Pharma maintained its commitment to delivering high-quality products. In H1 FY27, the company passed 12 regulatory inspections and upheld its record of avoiding classifications like
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.